Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -1.96% | -5.66% | -27.54% |
04-30 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
04-10 | Top Premarket Gainers | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.54% | 44.9M | |
-3.30% | 102B | |
+1.48% | 96.09B | |
+2.13% | 22.28B | |
-16.60% | 21.4B | |
-9.10% | 18.14B | |
-39.98% | 17.02B | |
-13.97% | 16.09B | |
+6.41% | 13.83B | |
+33.67% | 11.97B |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- IN8bio : B. Riley Starts IN8bio at Buy with $19 PT, Ascribes Value to Glioblastoma Multiforme Program